[SCHEDULE 13G/A] Blueprint Medicines Corporation SEC Filing
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 375,000 shares of Blueprint Medicines Corp common stock, equal to 0.6% of the class based on 64,733,629 shares outstanding as reported by the issuer. The filing shows both reporting persons have sole voting power and sole dispositive power for the reported shares. Avoro is identified as an investment adviser and Dr. Aghazadeh as the portfolio manager and controlling person; the shares are held for investment purposes on behalf of Avoro Life Sciences Fund LLC and are stated to be held in the ordinary course of business with no intent to change or influence control.
Avoro Capital Advisors LLC e Behzad Aghazadeh segnalano la titolarit脿 effettiva di 375.000 azioni ordinarie di Blueprint Medicines Corp, pari a 0,6% della classe, calcolato su 64.733.629 azioni in circolazione come riportato dall'emittente. La comunicazione indica che entrambe le parti segnalanti detengono il diritto esclusivo di voto e il diritto esclusivo di disposizione sulle azioni segnalate. Avoro 猫 indicata come consulente di investimento e il Dr. Aghazadeh come gestore del portafoglio e soggetto controllante; le azioni sono detenute a fini di investimento per conto di Avoro Life Sciences Fund LLC e sono dichiarate detenute nel normale corso dell'attivit脿 senza intenzione di modificare o influenzare il controllo.
Avoro Capital Advisors LLC y Behzad Aghazadeh informan la propiedad beneficiaria de 375.000 acciones ordinarias de Blueprint Medicines Corp, equivalentes al 0,6% de la clase, sobre la base de 64.733.629 acciones en circulaci贸n seg煤n informa el emisor. La presentaci贸n indica que ambas personas informantes tienen el poder exclusivo de voto y el poder exclusivo de disposici贸n sobre las acciones notificadas. Avoro se identifica como asesor de inversiones y el Dr. Aghazadeh como gestor de cartera y persona controladora; las acciones se mantienen con fines de inversi贸n en nombre de Avoro Life Sciences Fund LLC y se declara que se conservan en el curso ordinario del negocio sin intenci贸n de cambiar o influir en el control.
Avoro Capital Advisors LLC鞕赌 Behzad Aghazadeh電� Blueprint Medicines Corp 氤错喌欤� 375,000欤茧ゼ 鞁れ唽鞙犿晿瓿� 鞛堨潓鞚� 鞁犼碃頄堨溂氅�, 鞚措姅 氚滍枆欤检嫕靾� 64,733,629欤� 旮办 頃措嫻 膦呺鞚� 0.6%鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滊鞐� 霐半ゴ氅� 霊� 氤搓碃鞛愲姅 鞁犼碃霅� 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓�瓿� 雼弲 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Avoro電� 韴瀽鞛愲靷 頇曥澑霅橂┌ Aghazadeh 氚曥偓電� 韽姼韽措Μ鞓� 毵る媹鞝� 瓴� 鞁れ鞝� 歆�氚办瀽搿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� Avoro Life Sciences Fund LLC毳� 雽�鞁犿暅 韴瀽 氇╈爜搿� 氤挫湢霅橂┌, 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢 欷戩澊瓿� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃� 鞚橂弰電� 鞐嗠嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Avoro Capital Advisors LLC et Behzad Aghazadeh d茅clarent la d茅tention b茅n茅ficiaire de 375听000 actions ordinaires de Blueprint Medicines Corp, soit 0,6% de la cat茅gorie, sur la base de 64聽733聽629 actions en circulation selon l'茅metteur. Le d茅p么t indique que les deux personnes d茅clarante disposent du pouvoir exclusif de vote et du pouvoir exclusif de disposition sur les actions d茅clar茅es. Avoro est identifi茅 comme conseiller en investissement et le Dr Aghazadeh comme gestionnaire de portefeuille et personne contr么lante聽; les actions sont d茅tenues 脿 des fins d'investissement pour le compte d'Avoro Life Sciences Fund LLC et sont d茅clar茅es d茅tenues dans le cours normal des affaires sans intention de modifier ou d'influencer le contr么le.
Avoro Capital Advisors LLC und Behzad Aghazadeh melden eine wirtschaftliche Beteiligung von 375.000 Aktien der Stammaktien von Blueprint Medicines Corp, entsprechend 0,6% der Klasse auf Basis von 64.733.629 ausgegebenen Aktien, wie vom Emittenten angegeben. Die Meldung weist aus, dass beide meldenden Personen alleiniges Stimmrecht und alleiniges Verf眉gungsrecht 眉ber die gemeldeten Aktien besitzen. Avoro wird als Investmentberater und Dr. Aghazadeh als Portfoliomanager und kontrollierende Person genannt; die Aktien werden zu Anlagezwecken im Namen von Avoro Life Sciences Fund LLC gehalten und sollen im gew枚hnlichen Gesch盲ftsverlauf gehalten werden, ohne die Absicht, die Kontrolle zu 盲ndern oder zu beeinflussen.
- None.
- None.
Insights
TL;DR: A small, non鈥慶ontrolling stake; unlikely to move the stock or corporate control dynamics.
The reported 375,000 shares (0.6%) represent a modest passive position relative to the issuer's 64.7 million share base. Because the reporting persons assert sole voting and dispositive power but classify the holding as investment-oriented and below the 5% disclosure threshold for greater influence, the position appears to be a routine institutional stake rather than a strategic control play. Market impact is likely limited unless the holder increases its stake materially.
TL;DR: Filing documents passive investment with sole authority over shares but no stated intent to alter control.
The Schedule 13G shows Avoro and Dr. Aghazadeh as beneficial owners with sole voting and dispositive powers for the 375,000 shares. The filing characterizes the stake as held in the ordinary course and not for the purpose of influencing control, and no group affiliation or coordinated action is disclosed. From a governance perspective, this is a standard disclosure of a small investor position without immediate governance implications.
Avoro Capital Advisors LLC e Behzad Aghazadeh segnalano la titolarit脿 effettiva di 375.000 azioni ordinarie di Blueprint Medicines Corp, pari a 0,6% della classe, calcolato su 64.733.629 azioni in circolazione come riportato dall'emittente. La comunicazione indica che entrambe le parti segnalanti detengono il diritto esclusivo di voto e il diritto esclusivo di disposizione sulle azioni segnalate. Avoro 猫 indicata come consulente di investimento e il Dr. Aghazadeh come gestore del portafoglio e soggetto controllante; le azioni sono detenute a fini di investimento per conto di Avoro Life Sciences Fund LLC e sono dichiarate detenute nel normale corso dell'attivit脿 senza intenzione di modificare o influenzare il controllo.
Avoro Capital Advisors LLC y Behzad Aghazadeh informan la propiedad beneficiaria de 375.000 acciones ordinarias de Blueprint Medicines Corp, equivalentes al 0,6% de la clase, sobre la base de 64.733.629 acciones en circulaci贸n seg煤n informa el emisor. La presentaci贸n indica que ambas personas informantes tienen el poder exclusivo de voto y el poder exclusivo de disposici贸n sobre las acciones notificadas. Avoro se identifica como asesor de inversiones y el Dr. Aghazadeh como gestor de cartera y persona controladora; las acciones se mantienen con fines de inversi贸n en nombre de Avoro Life Sciences Fund LLC y se declara que se conservan en el curso ordinario del negocio sin intenci贸n de cambiar o influir en el control.
Avoro Capital Advisors LLC鞕赌 Behzad Aghazadeh電� Blueprint Medicines Corp 氤错喌欤� 375,000欤茧ゼ 鞁れ唽鞙犿晿瓿� 鞛堨潓鞚� 鞁犼碃頄堨溂氅�, 鞚措姅 氚滍枆欤检嫕靾� 64,733,629欤� 旮办 頃措嫻 膦呺鞚� 0.6%鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滊鞐� 霐半ゴ氅� 霊� 氤搓碃鞛愲姅 鞁犼碃霅� 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓�瓿� 雼弲 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Avoro電� 韴瀽鞛愲靷 頇曥澑霅橂┌ Aghazadeh 氚曥偓電� 韽姼韽措Μ鞓� 毵る媹鞝� 瓴� 鞁れ鞝� 歆�氚办瀽搿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� Avoro Life Sciences Fund LLC毳� 雽�鞁犿暅 韴瀽 氇╈爜搿� 氤挫湢霅橂┌, 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢 欷戩澊瓿� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃� 鞚橂弰電� 鞐嗠嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
Avoro Capital Advisors LLC et Behzad Aghazadeh d茅clarent la d茅tention b茅n茅ficiaire de 375听000 actions ordinaires de Blueprint Medicines Corp, soit 0,6% de la cat茅gorie, sur la base de 64聽733聽629 actions en circulation selon l'茅metteur. Le d茅p么t indique que les deux personnes d茅clarante disposent du pouvoir exclusif de vote et du pouvoir exclusif de disposition sur les actions d茅clar茅es. Avoro est identifi茅 comme conseiller en investissement et le Dr Aghazadeh comme gestionnaire de portefeuille et personne contr么lante聽; les actions sont d茅tenues 脿 des fins d'investissement pour le compte d'Avoro Life Sciences Fund LLC et sont d茅clar茅es d茅tenues dans le cours normal des affaires sans intention de modifier ou d'influencer le contr么le.
Avoro Capital Advisors LLC und Behzad Aghazadeh melden eine wirtschaftliche Beteiligung von 375.000 Aktien der Stammaktien von Blueprint Medicines Corp, entsprechend 0,6% der Klasse auf Basis von 64.733.629 ausgegebenen Aktien, wie vom Emittenten angegeben. Die Meldung weist aus, dass beide meldenden Personen alleiniges Stimmrecht und alleiniges Verf眉gungsrecht 眉ber die gemeldeten Aktien besitzen. Avoro wird als Investmentberater und Dr. Aghazadeh als Portfoliomanager und kontrollierende Person genannt; die Aktien werden zu Anlagezwecken im Namen von Avoro Life Sciences Fund LLC gehalten und sollen im gew枚hnlichen Gesch盲ftsverlauf gehalten werden, ohne die Absicht, die Kontrolle zu 盲ndern oder zu beeinflussen.
FAQ
How many Blueprint Medicines (BPMC) shares does Avoro report owning?
What percentage of Blueprint Medicines does the 375,000 shares represent?
Does Avoro or Behzad Aghazadeh have voting or dispositive power over the shares?
Was the stake acquired for investment purposes or to influence control of Blueprint Medicines?
Who are the reporting persons listed on the Schedule 13G/A for BPMC?
Does this filing indicate ownership above the 5% threshold?
